Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 2
Submit an article Journal homepage
14
Views
0
CrossRef citations to date
0
Altmetric
Editorial

IGF-I in early-stage Alzheimer’s diesease: a potential therapeutic target?

Emmanuelle Duron Department of Geriatrics, AP-HP, Groupe Hospitalier Paris-Centre, Broca Hospital, 54–56 rue Pascal, Paris 75013, France and Université Paris Descartes, Sorbonne Paris Cité, EA 4468, 15 Rue de L’école de Médecine, Paris 75006, France and Centre de Psychiatrie et Neuroscience, Inserm UMR-S894, 2 Ter Rue d’Alesia, Paris 75014, France. [email protected]
,
Jacques Epelbaum Centre de Psychiatrie et Neuroscience, Inserm UMR-S894, 2 ter rue d’Alesia, Paris 75014, France
&
Olivier Hanon Department of Geriatrics, AP-HP, Groupe Hospitalier Paris-Centre, Broca Hospital, 54–56 rue Pascal, Paris 75013, France and Université Paris Descartes, Sorbonne Paris Cité, EA 4468, 15 Rue de L’école de Médecine, Paris 75006, France
Pages 97-99 | Published online: 10 Jan 2014

References

  • Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 377(9770), 1019–1031 (2011).
  • Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat. Med. 8(12), 1390–1397 (2002).
  • Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 272(31), 19547–19553 (1997).
  • Kalmijn S, Janssen JA, Pols HA, Lamberts SW, Breteler MM. A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J. Clin. Endocrinol. Metab. 85(12), 4551–4555 (2000).
  • Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T. Relationship between serum insulin-like growth factor-1 levels and Alzheimer’s disease and vascular dementia. J. Am. Geriatr. Soc. 53(10), 1748–1753 (2005).
  • Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer’s disease. J. Alzheimers Dis. 12(4), 285–290 (2007).
  • Vargas T, Martinez-Garcia A, Antequera D et al. IGF-I gene variability is associated with an increased risk for AD. Neurobiol. Aging 32(3), 556.e3–556. e11 (2011).
  • Duron E, Funalot B, Brunel N et al.Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer’s disease. J. Clin. Endocrinol. Metab. 97(12), 4673–4681(2012).
  • Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256(3), 183–194 (2004).
  • Friedrich N, Haring R, Nauck M et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J. Clin. Endocrinol. Metab. 94(5), 1732–1739 (2009).
  • Okereke OI, Kang JH, Ma J, Gaziano JM, Grodstein F. Midlife plasma insulin-like growth factor I and cognitive function in older men. J. Clin. Endocrinol. Metab. 91(11), 4306–4312 (2006).
  • Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol. Aging 28(1), 135–142 (2007).
  • Niikura T, Hashimoto Y, Okamoto T et al. Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer’s V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J. Neurosci. 21(6), 1902–1910 (2001).
  • Nishijima T, Piriz J, Duflot S et al. Neuronal activity drives localized blood–brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 67(5), 834–846 (2010).
  • Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer’s-like neuropathology in rodents: new cues into the human disease? Neurobiol. Aging 27(11), 1618–1631 (2006).
  • Talbot K, Wang HY, Kazi H et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122(4), 1316–1338 (2012).
  • Doulah AH, Rohani AH, Khaksari Haddad M et al. The effect of peripheral administration of growth hormone on AD-like cognitive deficiency in NBM-lesioned rats. Neurosci. Lett. 466(1), 47–51 (2009).
  • Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 71(21), 1702–1708 (2008).
  • Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 9(11), 1118–1127 (2010).
  • Baker LD, Barsness SM, Borson S et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch. Neurol. 69(11), 1420–1429 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.